Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CellPress: Emerging Field of OV Based Cancer Immunotherapy

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Dec 07, 2022 2:38pm

210 Views

Post# 35157073

RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy

KSW,

Thanks for this wise and thoughtful post. I agree with you completely. Probably that is because we have watched the same events for the last 10 years or so.

Just wait.

Ignore the current S/P

The Goblet results and indisputable, as illustrated by Fast Track Designation.

Bracelet only has to look as good as it did last time to confirm those results, which got us our first fast track.

All the other results our out there in the world's top science/medicine/oncology journals. It is all true.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?